EGFRI-induced dermal toxicity
Conditions
Interventions
Experimental group :EGFRI combined with Xiaozhenfang granule
control group:EGFRI combined with Xiaozhenfang granule simulation agent
Sponsors
Jiangsu Province Hospital on Integration of Chinese and Western Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: (1) Patients who meet the diagnostic criteria for NSCLC and have been treated with EGFRI (gefitinib, erlotinib, ectinib, afatinib, metrotinib, osititinib, ametinib, etc.) for EGFR mutations through pathological and genetic testing. (2) patients with unconsciousness disorder; (3) PS score 3 months; (4) Aged 18-85; (5) no serious damage to the heart, liver, kidney or hematopoietic system; (6) Participate in clinical research voluntarily and sign informed consent.
Exclusion criteria
Exclusion criteria: (1) Present rash of any grade; (2) Past receipt of EGFRI; (3) are receiving topical antibiotics, steroids or oral antibiotics, immunomodulators and other medications that may treat or prevent the rash; (4) Participate in any other clinical study; (5) Patients who cannot take oral medication; (6) Patients with mental illness who cannot cooperate; (7) Pregnant women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NCI-CTCAE 5.0 Classification of adverse reactions; | — |
Secondary
| Measure | Time frame |
|---|---|
| EORTC QLQ-C30 Quality of Life score;Patient Anxiety and Depression Scale (HADS) score;EGFRI dose;Disease control rate, efficacy evaluation (RESIST 1.1); | — |
Countries
China
Contacts
Public ContactXing Haiyan
Jiangsu Province Hospital on Integration of Chinese and Western Medicine
Outcome results
None listed